Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2014

View Archived Issues

GeNeuro and Servier to develop drug addressing a causal factor of multiple sclerosis

Prothena reports phase I/II data for NEOD-001 in AL amyloidosis and initiates phase III trial

Phase III control patients with newly diagnosed GBM cleared to receive Novocure's TTFields

Roche to acquire Ariosa Diagnostics

ADMA's phase III study of RI-002 for primary immune deficiency disease meets primary endpoint

BeyondSpring Pharmaceuticals to conduct phase III trial of plinabulin in NSCLC

Bayer files for E.U. approval of BAY-81-8973 for hemophilia A

Evidence of autoimmune predisposition in Down Syndrome

Interim phase I/II results for TPI-287 plus bevacizumab in patients with recurrent GBM

Array BioPharma regains rights to binimetinib from Novartis

Results for anacetrapib from phase III REALIZE study

Phase II results presented for ARC-520 in patients with chronic HBV infection

Anti-CD19 MAb granted orphan status for diffuse large B-cell lymphoma

The University of Szeged divulges inhibitors of Abeta neurotoxicity

Janssen R&D Ireland reports development of TLR agonists

MedoLution presents new BTK/EGFR inhibitors

U.S. researchers present novel inhibitors of protozoal CDPK1

DPI-289, a dual delta agonist/mu antagonist, shows promise in models of Parkinson's disease

Michael J. Fox Foundation for Parkinson's Research awards grant to Gismo Therapeutics

FDA approves ruxolitinib for polycytemia vera

TxCell initiates phase IIb study of Ovasave for refractory Crohn's disease

PTC Therapeutics launches Translarna for nonsense mutation DMD

FDA gives tentative approval to abacavir/lamivudine pediatric formulations

Armgo Pharma and Servier advance ARM-210 into clinical program for DMD

FDA grants Cellectar's [131I]CLR-1404 orphan drug designation for multiple myeloma

First subject dosed in phase I study of prime-boost regimen of Ebola candidate vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...